10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended April 30, 2014

or

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the transition period from ______to______.

Commission File Number: 333-177122

HEALTH ADVANCE INC.

 (Exact name of registrant as specified in its Charter)

WYOMING	46-0525223
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

3651 Lindell Rd. Suite D155

Las Vegas, NV, 89103

 (Address of Principal Executive Offices)(Zip Code)

702-943-0309

 (Registrants telephone number, including area code)

N/A

(Former name, or former address and former fiscal year if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company filer. See the definitions of “large accelerated filer,” “accelerated filer” and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer	o		Accelerated Filer	o
Non-Accelerated Filer	o	(Do not check if a smaller reporting company)	Smaller Reporting Company	þ

Indicate by check mark whether the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. Yes o No þ

Indicate the number of shares outstanding of each of the issuer’s classes of common stock. As of June 16, 2014, there were 24,520,000 shares of the issuer’s common stock issued and outstanding.

HEALTH ADVANCE INC.

FORM 10-Q

April 30, 2014

INDEX

PART I-- FINANCIAL INFORMATION
Item 1.	Condensed Financial Statements - Unaudited	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	12
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	19
Item 4.	Controls and Procedures	19
PART II-- OTHER INFORMATION
Item 1.	Legal Proceedings	19
Item 1A.	Risk Factors	19
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	19
Item 3.	Defaults Upon Senior Securities	19
Item 4.	Mine Safety Disclosures	19
Item 5.	Other Information	19
Item 6.	Exhibits	19
SIGNATURE		20

2

PART I – FINANCIAL INFORMATION

Item 1. Condensed Financial Statements

HEALTH ADVANCE INC.

(A Development Stage Company)

CONDENSED FINANCIAL STATEMENTS

April 30, 2014

CONTENTS

PAGE-4	CONDENSED BALANCE SHEETS AS AT APRIL 30, 2014 AND AS AT JULY 31, 2013 (UNAUDITED)
PAGE-5-6	CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS FOR THE THREE AND NINE MONTHS ENDED APRIL 30, 2014 AND 2013 AND FOR THE PERIOD FROM APRIL 14, 2010 (INCEPTION) TO APRIL 30, 2014 (UNAUDITED)
PAGE-7	CONDENSED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED APRIL 30, 2014 AND 2013 AND FOR THE PERIOD APRIL 14, 2010 (INCEPTION) TO APRIL 30, 2014 (UNAUDITED)
PAGE-9	NOTES TO CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

3

HEALTH ADVANCE INC.

(A Development Stage Company)

CONDENSED BALANCE SHEETS

AS AT APRIL 30, 2014 AND JULY 31, 2013 (UNAUDITED)

(Expressed in United States Dollars)

	April 30,			July 31,
	2014			2013
	$			$
ASSET
CURRENT ASSET
Cash		—			526
TOTAL ASSET		—			526
LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES
Accounts payable and accrued liabilities		33,340			24,389
Advances from a shareholder (Note 4)		53,955			34,398
TOTAL LIABILITIES		87,295			58,787
STOCKHOLDERS' DEFICIT
Authorized:
500,000,000 common stock, par value $0.001
Issued and outstanding: (Note 7)
24,520,000 common stock as at April 30, 2014 (July 31, 2013: 24,520,000 common stock)		24,520			24,520
Additional paid-in capital		162,080			144,080
Common stock to be issued (Note 7)		42,500			36,500
Deficit accumulated during the exploration stage		(316,395	)		(263,361	)
TOTAL STOCKHOLDERS' DEFICIT		(87,295	)		(58,261	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT		—			526

See accompanying notes

4

HEALTH ADVANCE INC.

(A Development Stage Company)

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

FOR THE THREE MONTHS ENDED APRIL 30, 2014 AND 2013 (UNAUDITED)

(Expressed in United States Dollars)

	Three			Three
	months ended			months ended
	April 30,			April 30,
	2014			2013
	$			$
SALES		—			—
COST OF SALES		—			—
GROSS PROFIT		—			—
EXPENSES
Professional fees		5,591			5,000
Office and general		1,881			5,873
Rent and occupancy		3,600			3,600
Consulting and management fees		6,000			21,000
Total expenses		17,072			35,473
Foreign exchange (loss) gain		—			(129	)
Loss before income taxes		(17,072	)		(35,602	)
Income taxes		—			—
NET AND COMPREHENSIVE LOSS FOR THE PERIOD		(17,072	)		(35,602	)
Loss per common share, basic and diluted		(0.0007	)		(0.0015	)
Weighted average number of common stock outstanding, basic and diluted		24,520,000			24,520,000

See accompanying notes

5

HEALTH ADVANCE INC.

(A Development Stage Company)

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

FOR THE NINE MONTHS ENDED APRIL 30, 2014 AND 2013 AND FOR THE PERIOD

FROM APRIL 14, 2010 (INCEPTION) TO APRIL 30, 2014 (UNAUDITED)

(Expressed in United States Dollars)

							Cumulative from
	Nine			Nine			April 14, 2010
	months ended			months ended			(inception) to
	April 30,			April 30,			April 30,
	2014			2013			2014
	$			$			$
SALES		—			—			100
COST OF SALES		—			—			69
GROSS PROFIT		—			—			31
EXPENSES
Professional fees		17,176			6,599			81,753
Office and general		6,849			11,814			28,882
Rent and occupancy		10,800			10,800			48,000
Consulting and management fees		18,000			33,000			157,000
Total expenses		52,825			62,213			315,635
Foreign exchange (loss) gain		(209	)		(129	)		(791	)
Loss before income taxes		(53,034	)		(62,342	)		(316,395	)
Income taxes		—			—			—
NET AND COMPREHENSIVE LOSS FOR THE PERIOD		(53,034	)		(62,342	)		(316,395	)
Loss per common share, basic and diluted		(0.0022	)		(0.0025	)
Weighted average number of common stock outstanding, basic and diluted		24,520,000			24,520,000

See accompanying notes

6

HEALTH ADVANCE INC.

(A Development Stage Company)

CONDENSED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED APRIL 30, 2014 AND 2013 AND FOR THE PERIOD

FROM APRIL 14, 2010 (INCEPTION) TO APRIL 30, 2014 (UNAUDITED)

(Expressed in United States Dollars)

							Cumulative from
	Nine			Nine			April 14, 2010
	months ended			months ended			(inception) to
	April 30,			April 30,			April 30,
	2014			2013			2014
	$			$			$
OPERATING ACTIVITIES
Net loss for the period		(53,034	)		(62,342	)		(316,395	)
Adjustments for non-cash items
Common stock issued for services		—			15,000			95,000
In-kind contribution of services		18,000			18,000			80,000
					—			—
Net change in non-cash working capital balances:
Prepaid expenses		—			1,164			—
Accounts payable and accrued liabilities		8,951			4,820			33,340
Net cash used in operating activities		(26,083	)		(23,358	)		(108,055	)
FINANCING ACTIVITIES
Proceeds from issuance of common stock		6,000			18,000			54,100
Advances from a shareholder		19,557			4,382			53,955
Net cash provided by financing activities		25,557			22,382			108,055
Net (decrease) increase in cash during the period		(526	)		(976	)		—
Cash, beginning of period		526			1,202			—
Cash, end of period		—			226			—

See accompanying notes

7

HEALTH ADVANCE INC.

(A Development Stage Company)

CONDENSED NOTES TO THE FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED APRIL 30, 2014 (UNAUDITED)

(Expressed in United States Dollars)

1. NATURE OF OPERATIONS AND ORGANIZATION

Health Advance Inc. (the "Company" or "Health Advance") was incorporated on April 14, 2010 in the State of Wyoming. The Company is a development stage company and is an online retailer of home medical products with operations in Canada and the United States of America (“USA”).

2. BASIS OF PRESENTATION

The condensed unaudited interim financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America for interim financial information and the SEC instructions to Form 10Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. All adjustments, consisting of normal recurring accruals, considered necessary for a fair presentation have been included. For further information, refer to the financial statements and footnotes thereto included in the Company’s annual report on Form 10K for the year ended July 31, 2013.

The Company is considered to be in the development stage as defined in Accounting Standards Codification (“ASC”) 915, Development Stage Entities. The Company has devoted substantially all of its efforts to business planning and development by means of raising capital for operations. The Company has also not realized any significant revenues. Among the disclosures required by ASC 915 are that the Company's financial statements be identified as those of a development stage company, and that the statements of operations and comprehensive loss, stockholders' equity (deficit) and cash flows disclose activity since the date of the Company's inception.

3. GOING CONCERN

These financial statements have been prepared assuming the Company will continue on a going concern basis. The Company has incurred losses since inception and the ability of the Company to continue as a going concern depends upon its ability to develop profitable operations and to continue to raise adequate financing. Management is actively targeting sources of additional financing to provide continuation of the Company’s operations. In order for the Company to meet its liabilities as they become due and to continue its operations, the Company is solely dependent upon its ability to generate such financing.

There can be no assurance that the Company will be able to continue to raise funds, in which case the Company may be unable to meet its obligations. Should the Company be unable to realize its assets and discharge its liabilities in the normal course of business, the net realizable value of its assets may be materially less than the amounts recorded in these financial statements.

These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

4. SUPPLEMENTAL CASH FLOW INFORMATION

During the three and nine months ended April 30, 2014, and 2013, and for the period from inception to April 30, 2014, there were no interest or taxes paid by the Company.

8

HEALTH ADVANCE INC.

(A Development Stage Company)

CONDENSED NOTES TO THE FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED APRIL 30, 2014 (UNAUDITED)

(Expressed in United States Dollars)

5. RELATED PARTY TRANSACTIONS

The transactions with related parties were in the normal course of operations and were measured at the exchange value which represented the amount of consideration established and agreed to by the parties. Related party transactions not disclosed elsewhere in these financial statements are as follows:

The Company paid rent and other overhead costs to a shareholder and director of the Company in the amount of $1,400 per month, totaling $4,200 and $12,600 for the three and nine months ended April 30, 2014 (Three and nine months ended April 30, 2013 - $4,200 and $8,400). This monthly charge includes the head office rent, phone, internet and other administrative services.  In addition, there were contributed management services of $2,000 per month totaling $6,000 and $18,000 for the three and nine months ended April 30, 2014 (Three and nine months ended April 30, 2013 - $6,000 and $18,000) from the controlling shareholder of the Company.

Advances from a shareholder of the Company as at April 30, 2014 were $53,955 (July 31, 2013 - $34,398). These advances are non-interest bearing, unsecured and with no specific terms of repayment.

6. RECENT ACCOUNTING PRONOUNCEMENTS

The Company’s management has evaluated all the recently issued accounting pronouncements through the filing date of these financial statements and does not believe that they will have a material effect on the Company’s financial position and results of operations.

7. EARNINGS PER SHARE

The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common stockholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Basic and diluted losses per share were the same at the reporting dates as there were no common stock equivalents outstanding at April 30, 2014 and 2013.

8. STOCKHOLDERS’ DEFICIT

COMMON STOCK - AUTHORIZED

As at April 30, 2014, the Company has 500,000,000 authorized shares of common stock with a par value of $0.001 per share.

COMMON STOCK - ISSUED AND OUTSTANDING

Company’s outstanding 24,520,000 shares of common stock ($24,520) as at April 30, 2014 consisted of the following:

On April 14, 2010 the Company issued 14,000,000 shares of common stock at $0.0001 per share to the founding shareholder for proceeds of $1,400.

9

HEALTH ADVANCE INC.

(A Development Stage Company)

CONDENSED NOTES TO THE FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED APRIL 30, 2014 (UNAUDITED)

(Expressed in United States Dollars)

8. STOCKHOLDERS’ DEFICIT (continued)

COMMON STOCK - ISSUED AND OUTSTANDING (continued)

During fiscal 2011, the Company completed non-brokered private placements of 920,000 shares of common stock at $0.01 per share for proceeds of $9,200.

During fiscal 2011, the Company issued 6,500,000 common stock for legal, consulting and web design services and directors fees.  These services were valued at $0.01 per share.  

On November 1, 2011 the Company issued 1,500,000 shares of common stock for professional services rendered.  These services were valued at $15,000.

On July 18, 2012 the Company issued 1,600,000 shares at $0.01 per share for a total of $16,000.

COMMON STOCK – TO BE ISSUED

Company’s 6,290,000 common stock to be issued amounting to $40,500 as at April 30, 2014 consist of the following:

On November 14, 2012, the Company received $10,000 in exchange for 2,000,000 shares of common stock at $0.005 per share.

In December 2012, the Company agreed to issue 1,000,000 shares of common stock valued at $0.01 per share for a total of $10,000 for web design services and repairs.  

In January 2013, the Company agreed to issue 500,000 shares of common stock valued at $0.01 per share for a total of $5,000 for consulting services.

In March 2013, the Company agreed to issue 800,000 shares at an issue price of $0.01 per share for a total of $8,000.

In June 2013, the Company agreed to issue 350,000 shares at an issue price of $0.01 per share for a total of $3,500.

In October 2013, the Company received $4,000 in exchange of 1,600,000 shares at an issue price of $0.0025 per share.

10

HEALTH ADVANCE INC.

(A Development Stage Company)

CONDENSED NOTES TO THE FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED APRIL 30, 2014 (UNAUDITED)

(Expressed in United States Dollars)

8. STOCKHOLDERS’ DEFICIT (continued)

COMMON STOCK – TO BE ISSUED (continued)

 In April 2014, the Company received $2,000 in exchange of 40,000 shares at an issue price of $0.05 per share.

OTHER INFORMATION

On February 14, 2013, the Company effected a 10-for-1 forward split of the Company’s issued and outstanding common shares. The Company’s issued and outstanding common shares were therefore increased from 2,452,000 to 24,520,000.  All per share amounts have been restated to reflect this stock split.

9. SUBSEQUENT EVENTS

The Company’s management has evaluated subsequent events through the filing date of these financial statements and has determined that there are no material subsequent events to report.

11

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following plan of operation provides information which management believes is relevant to an assessment and understanding of our results of operations and financial condition. The discussion should be read along with our financial statements and notes thereto. This section includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our predictions.

Overview

Health Advance Inc. (the “Company”) was incorporated on April 14, 2010 in Wyoming. The Company is an on-line retailer of home medical products with operations in Canada and the United States, and with administration and infrastructure supported globally.  Our strategy is to attract opportunities in the health care industry through the development and growth of our existing web site www.healthadvancemd.com.   We believe we can operate more cost efficiently and compete as a discounter that delivers value and low cost branded lines of home medical care products together with valuable customer care that is currently missing in the marketplace.  Our goal is to become our customers’ single source for low cost health care supplies, by meeting all of our customer’s needs.

From inception to April 30, 2014 we have incurred a net loss of $316,395.  The ability of the Company to continue as a going concern depends upon its ability to raise adequate financing and develop profitable operations. If we cannot generate sufficient revenues from our services, we may have to delay the implementation of our business plan. Management is actively targeting sources of additional financing to provide continuation of the Company’s operations. In order for the Company to meet its liabilities as they come due and to continue its operations, the Company is solely dependent upon its ability to generate such financing.

The Company is actively seeking financing for its current business operation.  The Company is optimistic that the financing will be secured and the going concern risk will be removed.  We are in discussions with various parties and believe a successful financing is likely. Any capital raised will be through either a private placement or a convertible debenture and will result in the issuance of shares of common stock from the Company’s authorized capital. 

On February 14, 2013, the Company affected a 10-for-1 forward split of the Company’s issued and outstanding common shares. The Company’s issued and outstanding common shares were therefore increased from 2,452,000 to 24,520,000.  All per share amounts have been restated to reflect this stock split.

Plan of Operation

We were incorporated on April 14, 2010 in Wyoming. Our business office is located at 3651 Lindell Road, Suite D#155, Las Vegas, NV, 89103.  Our telephone number is 702-943-0309. We were founded by Jordan Starkman, who serves as our President and Director.  In addition, Domenico Pascazi was appointed as a director in March 2011.  On February 12, 2013, Mr. Pascazi resigned from his position as a member of the board of directors. Mr. Pascazi’s resignation was not a result of any disagreement with the Company or its executive officers, or any matter relating to the Company’s operations, policies or practices.

12

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)

We are an on-line retailer of home medical products with operations in Canada and the United States, and with administration and infrastructure supported globally.  Our strategy is to attract opportunities in the health care industry through the development and growth of our existing web site www.healthadvancemd.com.  We believe we can operate more cost efficiently and compete as a discounter that delivers value and low cost branded lines of home medical care products together with valuable customer care that is currently missing in the marketplace.  Our goal is to become our customers’ single source for low cost health care supplies, by meeting all of our customers’ needs.

We strive to offer health care professionals, medical distributors and consumers the highest quality brands and products at the most affordable prices. We expect to achieve this by forming relationships with suppliers that will be able to provide us with preferred prices once we are able to make bulk purchases.

In the fiscal year 2014, we plan to build our business across four key product categories including: (1) respiratory, (2) diabetes, (3) ostomy, and (4) mastectomy supplies. Our growth plan is to generate operating revenues during fiscal years 2014-2015.  We plan to complete a financing in the fiscal year 2014. We have not yet entered into any agreements with any parties with respect to obtaining financing for the Company.

If we are unable to obtain financing on reasonable terms, we could be forced to delay or scale back our plans for expansion. In addition, such inability to obtain financing on reasonable terms could have a material adverse effect on our business, operating results, or financial condition.

If we are able to obtain financing, we plan to implement both online and offline marketing and customer engagement campaigns for both our traditional durable medical products and our four key product areas mentioned above. We intend to target consumers with on-line marketing, and businesses, including various senior care facilities, with direct mail, telemarketing and flyer campaigns. Initially, we will target small to medium size facilities. We also intend to launch our direct mail onsite flyer campaigns and outbound calling campaigns in unison to increase the frequency and awareness of HealthAdvanceMD. We expect to replace and expand any existing major wholesaler relationships we currently work with by fiscal years 2014-2015.  Further, during this expected time frame, we plan to establish direct-from-manufacturer programs for our four key growth markets. We intend to continue to run our durable medical products business through the existing wholesaler relationships given the large range of product SKUs in the durable medical product category where we carry no less than a selection of nearly 2,000 products. No steps have been taken thus far to secure customers for our products.

The Company has started the process of preparing for an online marketing campaign.  The Company has a relationship with AGS Cybertech located in India who will manage and coordinate all of our online marketing efforts.  The campaign will include internet banner ads, search engine optimization, and social media optimization.  All banner advertising will be strategically placed with various click per view programs as part of our overall sales and marketing plan.

In our key growth areas we plan to focus on reducing and concentrating the number of product SKUs in each growth category in order to create leverage with our supply chain across selected relationships with respiratory, diabetes, ostomy and mastectomy suppliers.  These new direct-from-manufacturer programs will primarily be drop ship programs and will essentially result in no new product inventory risks.  They will be predominantly product substitution strategies where direct manufacturers carry the inventory risk in order to get shelf space within our business to consumer e-commerce property www.healthadvancemd.com and other sales channels.  These programs will be based on committed but non-binding contracted volume from us with each manufacturer, but where the manufacturer still carries the inventory, marketing investment, and the majority of the time continues to handle drop shipments direct to our customers and sales channels.

13

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)

The first tranche of these direct-from-manufacturer programs is expected to be with North America based manufacturers given a tendency for higher quality product, margins and their ability to handle inventory and direct shipments to our customers.  We also plan to evaluate a select number of overseas supplier relationships if we identify that a select overseas direct supplier can and will meet our delivery, financing and quality and return warranty terms.  As a result of these supply chain improvements we expect to increase our net revenues based on margin improvements of an average of 20-25% and this does not include factoring in even higher margins if we choose to source from overseas markets.

We expect that these new product launches will be outlined and planned within the 2014-2015 fiscal years and the beginning of fiscal year 2014, once our financing is completed.  During the next 24 months, we plan to work with our manufacturing partners to develop and finalize no less than two new product lines within each core product group for respiratory, diabetes, ostomy and mastectomy supplies and launch them by the second half of year 2.  Together with our manufacturer partners we intend to develop and test market and then finalize our packaging and product features and licensing requirements by the end of July 2015.

In addition to attempting to achieve supply chain optimization by the first quarter of  2015, which we intend to result in reduced overall cost of goods, we also plan to drive top line growth with a major marketing initiative for new products. No formal products have been discussed as of yet. By the end of the second quarter 2015, we intend to achieve the 3 key milestones outlined above including: (1) entering into new growth markets, (2) optimizing our supply chain, and (3) launching new product lines in our new growth from existing product line sales in growth markets for respiratory, diabetes, ostomy and mastectomy supplies through a margin optimized supply chain; a contribution from our traditional durable medical products businesses through existing wholesaler channels and from new products launched.

We have estimated that we will incur minimum expenses equal to $15,000 in the year following our July 31, 2013 year-end in order to maintain our business operations.  However, if we conduct a financing, we will devote the capital raised to operational expenses as indicated below. The Company will attempt to complete a financing for a minimum of $200,000 within the 12-month period following the Company’s 2014 year-end.  Any capital raised will be through either a private placement or a convertible debenture and will result in the issuance of common shares from the Company’s authorized capital.

Web Development and Maintenance	$	5,000
Legal/Accounting	$	15,000
Computer hardware and software systems	$	10,000
Advertising  and Marketing	$	130,000
General and administrative	$	10,000
Salaries and Customer Service	$	25,000
Telephone	$	1,000
Travel	$	4,000
Total Expenses	$	200,000

The above represents managements’ best estimate of our cash requirements based on our business plans and current market conditions. The above is based on our ability to raise sufficient financing and generate adequate revenues to meet our cash flow requirements. The actual allocation between expenses may vary depending on the actual funds raised and the industry and market conditions over the next 12 months following our July 31, 2013 year-end.

14

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)

The Company is currently negotiating financing in the amount of $200,000 to further the Company’s business operations.  Any capital raised will likely be through either a private placement or a convertible debenture and will likely result in the issuance of common shares from the Company’s authorized capital.

If we are able to complete a financing through a private offering for a minimum of $200,000 within the 12 month period following our July 31, 2013 year-end, we expect to replace and expand any existing major wholesaler relationships we currently work with by the beginning of year two following our July 31, 2013 year-end. Further, during this expected time frame, we plan to establish direct-from-manufacturer programs for our four key growth markets in order to achieve improved margin of between 25-35%.  We will continue, however, to run our durable medical products business through the existing wholesaler relationships given the large range of product SKUs in the durable medical product category where we carry no less than a selection of nearly 2,000 products.

Results of Operations

For the three and nine months ended April, 30 2014 and 2013

For the three and nine months ended April 30, 2014 and 2013 we did not have any sales and have generated no revenues. The Company’s on-line web site www.healthadvancemd.com encountered a virus/worm and subsequently underwent extensive repairs that accounted for the Company’s lack of sales. We expect to generate increased sales once our advertising campaign begins.

Operating expenses for the three and nine months ended April 30, 2014 were $17,072 and $52,825, respectively as compared to operating expenses of $35,473 and $62,213 for the three and nine months ended April 30, 2013, respectively.  The operating expenses were primarily attributed to professional fees, consulting fees, web design fees, rent and other general overhead. The decrease in overall expenses of $18,401 and $9,388 for the three and nine  months ended April 30, 2014 as compared to 2013 is mainly attributed to a consulting charge of $5,000 and web design and services repair of $10,000 during the nine months ended April 30, 2013, which was not there during the nine months ended April 30, 2014.  Further, the increase in professional fees from $6,599 for the nine months ended April 30, 2013 to $17,176 for the nine months ended April 30, 2014 mainly attributable to engaging an external accountant.

Net losses for the three and nine months ended April 30, 2014 were $17,072 and $53,034, respectively as compared to net losses of $35,602 and $62,342 for the three and nine months ended April 30, 2013, respectively. The decrease in net losses is attributable to the decrease in consulting charges offset by the increase in professional fees as explained above.

During the period from inception (April 14, 2010) to April 30, 2014 the total operating expenses were $315,635 and the net loss was $316,395.

During the three and nine months ended April 30, 2014 the director’s contributed services totaled $6,000 and $18,000, respectively. These services were included in the additional paid-in capital.

During the three and nine months ended April 30, 2014 we operated from a premises leased by a shareholder. The costs of this premises and other general and administrative expenses paid on our behalf during the three and nine months ended April 30, 2014 totaled $4,200 and $12,600, respectively. These expenses are payable to the shareholder and included in current liabilities.

During the period from inception (April 14, 2010) to April 30, 2014, we had no provision for income taxes due to the net operating losses incurred.

15

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)

Liquidity and Capital Resources

As of April 30, 2014, we had a cash balance of $Nil and a working capital deficit of $87,295.

In October 2013, the Company received $4,000 in exchange of 1,600,000 shares to be issued at a price of $0.0025 per share.

In April 2014, the Company received $2,000 in exchange of 40,000 shares to be issued at a price of $0.05 per share.

The Company is currently seeking funding for our continued operations.  The Company intends to raise a minimum of $200,000 and a maximum of $500,000 in order to continue the introduction of the www.healthadvancemd.com e-commerce site to the retail community and health care community.  To achieve our goals the Company expects to commit the majority of its funding to the advertising of the Company’s web site. There is no assurance that the Company will be able to raise the capital required to complete its goal and objectives and the Company is currently seeking capital to further its business plan.  We are planning to raise funds through either debt or issuing shares of our common stock in order to achieve our business goals. The issuance of additional shares or securities convertible into any such shares may dilute the percentage ownership of our current stockholders. There are no agreements with any parties at this point in time for additional funding; however, we are in discussions with various funders in the United States.

We believe we can satisfy our cash requirements for the next twelve months with our expected revenues and if needed an additional loan from our director, Jordan Starkman.  We cannot assure investors that adequate revenues will be generated and there is no current loan commitment in place between the Company and Jordan Starkman. However, the success of our operations is dependent on attaining adequate revenue. In the absence of our projected revenues, we may be unable to proceed with our plan of operations or we may require financing to achieve our profit, revenue, and growth goals.

We anticipate that our fixed costs made up of legal and accounting and general and administrative expenses for the next 12 months will total approximately $25,000. Legal and accounting expenses of $15,000 represents the minimum funds needed to sustain operations. The $25,000 will be financed through the Company’s cash on hand, additional financing, net sales and if needed, an advance from our officer and director, Jordan Starkman. We do not anticipate the purchase or sale of any significant equipment. We also do not expect any significant additions to the number of employees, until financing is raised. The foregoing represents our best estimate of our cash needs based on our current business condition. The exact allocation, purposes and timing of any monies raised in subsequent private financings may vary significantly depending upon the exact amount of funds raised and our progress with the execution of our business plan. It is currently expected that the Company will spend an additional $175,000 in variable costs relating to marketing and business development that will be funded from future financings.

In the event we are not successful in reaching our initial revenue targets, we will need additional funds to proceed with our business plan for the development and marketing of our core services. Should this occur, we would likely seek additional financing to support the continued operation of our business. We anticipate that depending on market conditions and our plan of operations, we may incur operating losses in the foreseeable future. Therefore, our auditors have raised substantial doubt about our ability to continue as a going concern.  

Recent Accounting Pronouncements

The management did not believe that recent accounting pronouncements issued by the FASB have a material impact on the Company’s present or future financial statements.

16

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)

Off-Balance Sheet Arrangements

We do not have any outstanding derivative financial instruments, off-balance sheet guarantees, interest rate swap transactions or foreign currency contracts.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not required for Smaller Reporting Companies.

Item 4.  Controls and Procedures

Disclosure of Controls and Procedures

Pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934 (“Exchange Act”), the Company carried out an evaluation, with the participation of the Company’s management, including the Company’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”) (the Company’s principal financial and accounting officer), of the effectiveness of the Company’s disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, the Company’s CEO and CFO concluded that the Company’s disclosure controls and procedures are not effective to ensure that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including the Company’s CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure, due to the material weaknesses identified below.

It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Report of Management on Internal Control over Financial Reporting

The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting for the Company.  Our internal control system was designed to, in general, provide reasonable assurance to the Company’s management and board regarding the preparation and fair presentation of published financial statements, but because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.  Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement to the Company's annual or interim financial statements will not be prevented or detected.

17

Item 4.  Controls and Procedures (continued)

Report of Management on Internal Control over Financial Reporting (continued)

In the course of management's assessment, we have identified the following material weaknesses in internal control over financial reporting:

● Segregation of Duties – As a result of limited resources, we did not maintain proper segregation of incompatible duties, namely the lack of an audit committee, an understaffed financial and accounting function, and the need for additional personnel to prepare and analyze financial information in a timely manner and to allow review and on-going monitoring and enhancement of our controls. The effect of the lack of segregation of duties potentially affects multiple processes and procedures.

 ● Maintenance of Current Accounting Records – We may from time to time fail to maintain our records that in reasonable detail accurately and fairly reflect the transactions of the Company. This weakness specifically affects the payments and purchase cycle and therefore we failed to maintain effective internal controls over the completeness and cut off of accounts payable, expenses and other capital transactions.

 ● Application of GAAP – We did not maintain effective internal controls relating to the application of generally accepted accounting principles in accounting for transactions in a foreign currency.

We are in the continuous process of improving our internal control over financial reporting in an effort to eliminate these material weaknesses through improved supervision and training of our staff, but additional effort is needed to fully remedy these deficiencies. Management has engaged a Certified Public Accountant as a consultant to assist with the financial reporting process in an effort to mitigate some of the identified weaknesses. The Company is still in its development stage and intends on hiring the necessary staff to address the weaknesses once revenue has been realized.

This annual report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the Company's registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the Company to provide only management's report in this annual report.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting that occurred during the quarter covered by this quarterly report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

18

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

We are currently not involved in any litigation that we believe could have a materially adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our company’s or our company’s subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

Item 1A. Risk Factors

Not required for Smaller Reporting Companies.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

In April 2014, the Company received $2,000 in exchange of 40,000 shares to be issued at a price of $0.05 per share. The shares were issued pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended.

Item 3. Defaults Upon Senior Securities

None

Item 4. Mine Safety Disclosures

Not Applicable

Item 5. Other Information

None

Item 6. Exhibits

31.1	Certification of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification of Principal Executive Officer and Principal Financial Officer of the Registrant pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

* The certification attached as Exhibit 32.1 accompanying this Quarterly Report on Form 10-Q is being furnished and is not deemed filed with the Securities and Exchange Commission.

19

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Health Advance, Inc.
By:	/s/ Jordan Starkman
	Jordan Starkman
	President, Chief Executive Officer, Chief Financial Officer (Duly Authorized Officer, Principal Executive Officer and Principal Financial Officer)
Dated: June16, 2014

20

EX-31.1

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Jordan Starkman, certify that:

1.	I have reviewed this Form 10-Q of Health Advance Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:
	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: June  16, 2014	By:	/s/ Jordan Starkman
		Jordan Starkman
		President and Chief Excecutive Officer, Chief Financial Officer.

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with this Quarterly Report of Health Advance Inc. (the “Company”), on Form 10-Q for the period ended April 30, 2014, as filed with the U.S. Securities and Exchange Commission on the date hereof, I, Jordan Starkman, President and Chief Excecutive Office and Chief Financial Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

(1)   Such Quarterly Report on Form 10-Q for the period ended April 30, 2014, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)   The information contained in such Quarterly Report on Form 10-Q for the period ended April 30, 2014, fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: June 16, 2014	By:	/s/ Jordan Starkman
		Jordan Starkman
		President and Chief Excecutive Officer, Chief Financial Officer.

XML

Supplemental Cash Flow Information

9 Months Ended

Apr. 30, 2014

Supplemental Cash Flow Information [Abstract]

SUPPLEMENTAL CASH FLOW INFORMATION

4. SUPPLEMENTAL CASH FLOW INFORMATION

During the three and nine months ended April 30, 2014, and 2013, and for the period from inception to April 30, 2014, there were no interest or taxes paid by the Company.

XML

Going Concern

9 Months Ended

Apr. 30, 2014

Going Concern [Abstract]

GOING CONCERN

3. GOING CONCERN

These financial statements have been prepared assuming the Company will continue on a going concern basis. The Company has incurred losses since inception and the ability of the Company to continue as a going concern depends upon its ability to develop profitable operations and to continue to raise adequate financing. Management is actively targeting sources of additional financing to provide continuation of the Company’s operations. In order for the Company to meet its liabilities as they become due and to continue its operations, the Company is solely dependent upon its ability to generate such financing.

There can be no assurance that the Company will be able to continue to raise funds, in which case the Company may be unable to meet its obligations. Should the Company be unable to realize its assets and discharge its liabilities in the normal course of business, the net realizable value of its assets may be materially less than the amounts recorded in these financial statements.

These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

XML

Condensed Balance Sheets (USD $)	Apr. 30, 2014	Jul. 31, 2013
CURRENT ASSET
Cash		$ 526
TOTAL ASSET		526
CURRENT LIABILITIES
Accounts payable and accrued liabilities	33,340	24,389
Advances from a shareholder (Note 4)	53,955	34,398
TOTAL LIABILITIES	87,295	58,787
STOCKHOLDERS' DEFICIT
Authorized: 500,000,000 common stock, par value $0.001 Issued and outstanding: (Note 7) 24,520,000 common stock as at April 30, 2014 (July 31, 2013: 24,520,000 common stock)	24,520	24,520
Additional paid-in capital	162,080	144,080
Common stock to be issued (Note 7)	42,500	36,500
Deficit accumulated during the exploration stage	(316,395)	(263,361)
TOTAL STOCKHOLDERS' DEFICIT	(87,295)	(58,261)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT		$ 526

XML

Nature of Operations and Organization

9 Months Ended

Apr. 30, 2014

Nature of Operations and Organization [Abstract]

NATURE OF OPERATIONS AND ORGANIZATION

1. NATURE OF OPERATIONS AND ORGANIZATION

Health Advance Inc. (the "Company" or "Health Advance") was incorporated on April 14, 2010 in the State of Wyoming. The Company is a development stage company and is an online retailer of home medical products with operations in Canada and the United States of America (“USA”).

XML

Basis of Presentation

9 Months Ended

Apr. 30, 2014

Basis of Presentation [Abstract]

BASIS OF PRESENTATION

2. BASIS OF PRESENTATION

The condensed unaudited interim financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America for interim financial information and the SEC instructions to Form 10Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. All adjustments, consisting of normal recurring accruals, considered necessary for a fair presentation have been included. For further information, refer to the financial statements and footnotes thereto included in the Company’s annual report on Form 10K for the year ended July 31, 2013.

The Company is considered to be in the development stage as defined in Accounting Standards Codification (“ASC”) 915, Development Stage Entities. The Company has devoted substantially all of its efforts to business planning and development by means of raising capital for operations. The Company has also not realized any significant revenues. Among the disclosures required by ASC 915 are that the Company's financial statements be identified as those of a development stage company, and that the statements of operations and comprehensive loss, stockholders' equity (deficit) and cash flows disclose activity since the date of the Company's inception.

XML

Condensed Balance Sheets (Parenthetical) (USD $)	Apr. 30, 2014	Jul. 31, 2013
Balance Sheets [Abstract]
Capital stock, par value	$ 0.001	$ 0.001
Capital stock, shares Authorized	500,000,000	500,000,000
Capital stock, shares Issued	24,520,000	24,520,000
Capital stock, shares outstanding	24,520,000	24,520,000

XML

Document and Entity Information	9 Months Ended
	Apr. 30, 2014	Jun. 16, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	Health Advance, Inc.
Entity Central Index Key	0001531477
Amendment Flag	false
Current Fiscal Year End Date	--07-31
Document Type	10-Q
Document Period End Date	Apr. 30, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		24,520,000

XML

Condensed Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended		48 Months Ended
	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014
Statements Of Operations and Comprehensive Loss [Abstract]
SALES					$ 100
COST OF SALES					69
GROSS PROFIT					31
EXPENSES
Professional fees	5,591	5,000	17,176	6,599	81,753
Office and general	1,881	5,873	6,849	11,814	28,882
Rent and occupancy	3,600	3,600	10,800	10,800	48,000
Consulting and management fees	6,000	21,000	18,000	33,000	157,000
Total expenses	17,072	35,473	52,825	62,213	315,635
Foreign exchange (loss) gain		(129)	(209)	(129)	(791)
Loss before income taxes	(17,072)	(35,602)	(53,034)	(62,342)	(316,395)
Income taxes
NET AND COMPREHENSIVE LOSS FOR THE PERIOD	$ (17,072)	$ (35,602)	$ (53,034)	$ (62,342)	$ (316,395)
Loss per common share, basic and diluted	$ (0.0007)	$ (0.0015)	$ (0.0022)	$ (0.0025)
Weighted average number of common stock outstanding, basic and diluted	24,520,000	24,520,000	24,520,000	24,520,000

XML

Earnings Per Share

9 Months Ended

Apr. 30, 2014

Earnings Per Share [Abstract]

EARNINGS PER SHARE

7. EARNINGS PER SHARE

The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common stockholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Basic and diluted losses per share were the same at the reporting dates as there were no common stock equivalents outstanding at April 30, 2014 and 2013.

XML

Recent Accounting Pronouncements

9 Months Ended

Apr. 30, 2014

Recent Accounting Pronouncements [Abstract]

RECENT ACCOUNTING PRONOUNCEMENTS

6. RECENT ACCOUNTING PRONOUNCEMENTS

The Company’s management has evaluated all the recently issued accounting pronouncements through the filing date of these financial statements and does not believe that they will have a material effect on the Company’s financial position and results of operations.

XML

Related Party Transactions (Details) (USD $)	3 Months Ended		9 Months Ended
	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013	Jul. 31, 2013
Related Party Transactions (Textual)
Monthly payment for rent and other overhead costs to a shareholder and director			$ 1,400
Total payment for rent and other overhead costs to a shareholder and director	4,200	4,200	12,600	8,400
Management services charges periodic basis			2,000
Management services charges monthly basis	6,000	6,000	18,000	18,000
Advances from a shareholder (Note 4)	$ 53,955		$ 53,955		$ 34,398

XML

Stockholders' Deficit

9 Months Ended

Apr. 30, 2014

Stockholders' Deficit [Abstract]

STOCKHOLDERS' DEFICIT

8. STOCKHOLDERS’ DEFICIT

COMMON STOCK - AUTHORIZED

As at April 30, 2014, the Company has 500,000,000 authorized shares of common stock with a par value of $0.001 per share.

COMMON STOCK - ISSUED AND OUTSTANDING

Company’s outstanding 24,520,000 shares of common stock ($24,520) as at April 30, 2014 consisted of the following:

On April 14, 2010 the Company issued 14,000,000 shares of common stock at $0.0001 per share to the founding shareholder for proceeds of $1,400.

During fiscal 2011, the Company completed non-brokered private placements of 920,000 shares of common stock at $0.01 per share for proceeds of $9,200.

During fiscal 2011, the Company issued 6,500,000 common stock for legal, consulting and web design services and directors fees.  These services were valued at $0.01 per share.  

On November 1, 2011 the Company issued 1,500,000 shares of common stock for professional services rendered.  These services were valued at $15,000.

On July 18, 2012 the Company issued 1,600,000 shares at $0.01 per share for a total of $16,000.

COMMON STOCK – TO BE ISSUED

Company’s 6,290,000 common stock to be issued amounting to $40,500 as at April 30, 2014 consist of the following:

On November 14, 2012, the Company received $10,000 in exchange for 2,000,000 shares of common stock at $0.005 per share.

In December 2012, the Company agreed to issue 1,000,000 shares of common stock valued at $0.01 per share for a total of $10,000 for web design services and repairs.  

In January 2013, the Company agreed to issue 500,000 shares of common stock valued at $0.01 per share for a total of $5,000 for consulting services.

In March 2013, the Company agreed to issue 800,000 shares at an issue price of $0.01 per share for a total of $8,000.

In June 2013, the Company agreed to issue 350,000 shares at an issue price of $0.01 per share for a total of $3,500.

In October 2013, the Company received $4,000 in exchange of 1,600,000 shares at an issue price of $0.0025 per share.

 In April 2014, the Company received $2,000 in exchange of 40,000 shares at an issue price of $0.05 per share.

OTHER INFORMATION

On February 14, 2013, the Company effected a 10-for-1 forward split of the Company’s issued and outstanding common shares. The Company’s issued and outstanding common shares were therefore increased from 2,452,000 to 24,520,000.  All per share amounts have been restated to reflect this stock split.

XML

Subsequent Events

9 Months Ended

Apr. 30, 2014

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

9. SUBSEQUENT EVENTS

The Company’s management has evaluated subsequent events through the filing date of these financial statements and has determined that there are no material subsequent events to report.

XML

Stockholders' Deficit (Details) (USD $)	0 Months Ended			1 Months Ended								12 Months Ended
	Feb. 14, 2013	Nov. 14, 2012	Apr. 14, 2010	Apr. 30, 2014	Oct. 31, 2013	Jun. 30, 2013	Mar. 31, 2013	Jan. 31, 2013	Dec. 31, 2012	Jul. 18, 2012	Nov. 30, 2011	Jul. 31, 2011	Jul. 31, 2013
Capital Stock (Textual)
Common stock, shares authorized				500,000,000									500,000,000
Common stock, par value				$ 0.001									$ 0.001
Common stock, shares outstanding	2,452,000			24,520,000									24,520,000
Common stock, value outstanding				$ 24,520
Issuance of common stock at inception, shares			14,000,000
Issuance of common stock at inception amount			1,400
Share Price			$ 0.0001							$ 0.01		$ 0.01
Issuance of common stock for cash, shares										1,600,000		920,000
Issuance of common stock for cash										16,000		9,200
Common stock shares issued for services, shares								500,000			1,500,000	6,500,000
Per share value of stock issued for service								$ 0.01				$ 0.01
Issuance of common stock for services								5,000			15,000
Common stock, outstanding				42,500									36,500
Common stock issuable shares				6,290,000
Common stock shares received in exchange, value		10,000		2,000	4,000
Common stock shares received in exchange, shares		2,000,000		40,000	1,600,000
Par value of common stock shares received in exchange		$ 0.005		$ 0.05	$ 0.0025
Common stock shares issued for web design services and repairs, shares									1,000,000
Par value of common stock shares issued for web design services and repairs									$ 0.01
Common stock shares issued for web design services and repairs, value									10,000
Common stock future issuance, Shares						350,000	800,000
Common stock future issuance, per share						$ 0.01	$ 0.01
Common stock future issuance, Value						$ 3,500	$ 8,000
Forward split for issued and outstanding common shares	10-for-1

XML

Condensed Statements of Cash Flows (USD $)	9 Months Ended		48 Months Ended
	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014
OPERATING ACTIVITIES
Net loss for the period	$ (53,034)	$ (62,342)	$ (316,395)
Adjustments for non-cash items
Common stock issued for services		15,000	95,000
In-kind contribution of services	18,000	18,000	80,000
Net change in non-cash working capital balances:
Prepaid expenses		1,164
Accounts payable and accrued liabilities	8,951	4,820	33,340
Net cash used in operating activities	(26,083)	(23,358)	(108,055)
FINANCING ACTIVITIES
Proceeds from issuance of common stock	6,000	18,000	54,100
Advances from a shareholder	19,557	4,382	53,955
Net cash provided by financing activities	25,557	22,382	108,055
Net (decrease) increase in cash during the period	(526)	(976)
Cash, beginning of period	526	1,202
Cash, end of period		$ 226

XML

Related Party Transactions

9 Months Ended

Apr. 30, 2014

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS

5. RELATED PARTY TRANSACTIONS

The transactions with related parties were in the normal course of operations and were measured at the exchange value which represented the amount of consideration established and agreed to by the parties. Related party transactions not disclosed elsewhere in these financial statements are as follows:

The Company paid rent and other overhead costs to a shareholder and director of the Company in the amount of $1,400 per month, totaling $4,200 and $12,600 for the three and nine months ended April 30, 2014 (Three and nine months ended April 30, 2013 - $4,200 and $8,400). This monthly charge includes the head office rent, phone, internet and other administrative services.  In addition, there were contributed management services of $2,000 per month totaling $6,000 and $18,000 for the three and nine months ended April 30, 2014 (Three and nine months ended April 30, 2013 - $6,000 and $18,000) from the controlling shareholder of the Company.

Advances from a shareholder of the Company as at April 30, 2014 were $53,955 (July 31, 2013 - $34,398). These advances are non-interest bearing, unsecured and with no specific terms of repayment.